RepliCel Life Sciences Announces Closing of Debt Settlement

Replicel Life Sciences Inc TSXV:RP Biotechnology, Medical Device, Genomics, 生物科技,医疗设备,基因组学
Published on: October 28, 2020

VANCOUVER, BC – October 28, 2020 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA: P6P2), (“RepliCel” or the “Company”), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce that, further to its News Release of August 19, 2020, it has received approval from the TSX Venture Exchange (the “Exchange”) to the issuance of 160,000 common shares (ach, a “Share”) in settlement of $28,800 owed by the Company to one creditor (the “Debt Settlement”). The Shares were issued on October 28, 2020. The Shares are subject to a statutory hold period of four months and one day after closing of the Debt Settlement.

About RepliCel Life Sciences

RepliCel is a regenerative medicine company focused on developing cell therapies for aesthetic and orthopedic conditions affecting what the Company believes is approximately one in three people in industrialized nations, including aging/sun‐damaged skin, pattern baldness, and chronic tendon degeneration. These conditions, often associated with aging, are caused by a deficit of healthy cells required for normal tissue healing and function. These cell therapy product candidates are based on RepliCel’s innovative technology, utilizing cell populations isolated from a patient’s healthy hair follicles.

The Company’s product pipeline is comprised of RCT–01 for tendon repair, RCS–01 for skin rejuvenation, and RCH–01 for hair restoration. RCH–01 is exclusively licensed in Asia to Shiseido Company and Shiseido is currently testing the product in Japan. RepliCel maintains the rights to RCH–01 for the rest of the world. RCT–01 and RCS–01 are exclusively licensed in Greater China to YOFOTO (China) Health Company. RepliCel and YOFOTO are currently co‐ developing these products in China. RepliCel maintains the rights to these products outside of Greater China.

RepliCel has also developed a proprietary injection device, RCI–02, and related consumables, which is expected to improve the administration of its cell therapy products and certain other injectables. YOFOTO has exclusively licensed the commercial rights for the RCI–02 device and consumables in Greater China for dermatology applications and is expected to first launch the product in Hong Kong upon it being CE marked. Please visit for additional information.

For more information, please contact:


Lee Buckler, CEO and President

Telephone: 604-248-8693 / [email protected]

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Biotechnology Genomics Medical Device